New combo aims to boost remission in Tough-to-Treat leukemia
NCT ID NCT06928376
First seen Mar 23, 2026 · Last updated May 15, 2026 · Updated 3 times
Summary
This study compares a new treatment (venetoclax plus the CACAG regimen) to the standard chemotherapy ("3+7") for adults aged 14-75 with newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if the new combination leads to more complete remissions after one course of treatment. About 160 participants will be enrolled at multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.